Journal
THORACIC CANCER
Volume 9, Issue 4, Pages 423-430Publisher
WILEY
DOI: 10.1111/1759-7714.12613
Keywords
ALK-rearrangement (ALK-R); ALK-tyrosine kinase inhibitor (TKI); anaplastic lymphoma kinase (ALK); detection platforms; non-small-cell lung cancer (NSCLC)
Categories
Funding
- National Natural Science Foundation of China [81372834]
Ask authors/readers for more resources
The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large-cell lymphoma. Since then, ALK has been associated with other types of cancers, including non-small-cell lung cancer (NSCLC). More than 19 different ALK fusion partners have been discovered in NSCLC, including EML4, KIF5B, KLC1, and TPR. Most of these ALK fusions in NSCLC patients respond well to the ALK inhibitor, crizotinib. In this paper, we reviewed fusion partner genes with ALK, detection methods for ALK-rearrangement (ALK-R), and the ALK-tyrosine kinase inhibitor, crizotinib, used in NSCLC patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available